312 related articles for article (PubMed ID: 30510457)
1. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream.
Goel G
Cancer Manag Res; 2018; 10():5895-5908. PubMed ID: 30510457
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
Atreya CE; Yaeger R; Chu E
Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.
Rachiglio AM; Sacco A; Forgione L; Esposito C; Chicchinelli N; Normanno N
Explor Target Antitumor Ther; 2020; 1(1):53-70. PubMed ID: 36046264
[TBL] [Abstract][Full Text] [Related]
4. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of metastatic colorectal cancer in the era of precision medicine.
Ciardiello F; Ciardiello D; Martini G; Napolitano S; Tabernero J; Cervantes A
CA Cancer J Clin; 2022 Jul; 72(4):372-401. PubMed ID: 35472088
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
[TBL] [Abstract][Full Text] [Related]
8. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
10. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
12.
Li ZN; Zhao L; Yu LF; Wei MJ
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
[TBL] [Abstract][Full Text] [Related]
13. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
Heinemann V; Douillard JY; Ducreux M; Peeters M
Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Saridaki Z; Georgoulias V; Souglakos J
World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status.
Pereira J; Alves F; Ferreira F; Vasconcelos de Matos L; Massena A; Martins A
Cureus; 2020 Feb; 12(2):e7035. PubMed ID: 32211268
[TBL] [Abstract][Full Text] [Related]
18. The State of the Art in Colorectal Cancer Molecular Biomarker Testing.
Pillai RK; Lopategui JR; Dhall D; Guindi M; Slavin T; Lofton-Day CE; Patterson SD
Adv Anat Pathol; 2016 Mar; 23(2):92-103. PubMed ID: 26849815
[TBL] [Abstract][Full Text] [Related]
19. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
20. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]